A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Phase 1 Active not recruiting 23 enrolled Yana Najjar Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.

Timeline

Start: 2018-02-07
Primary completion: 2028-01-31
Completion: 2029-12-31

Publications

Giannitti G, Paganoni AJJ, Marchesi S, Garavaglia R, Fontana F. Mitochondrial bioenergetics and networks in melanoma: an update. Apoptosis. 2025 Oct;30(9-10):2042-2056. doi: 10.1007/s10495-025-02155-4. Epub 2025 Jul 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	500 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	400 mg	Intravenous

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Summary

Timeline

Publications

Drugs

Indications